SEARCH:   Advanced

Blood, 1 June 2008, Vol. 111, No. 11, pp. 5403-5410. Prepublished online as a Blood First Edition Paper on February 19, 2008; DOI 10.1182/blood-2007-11-121558. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-11-121558v1 111/11/5403    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Winston, D. J. Articles by Boeckh, M. PubMed PubMed Citation Articles by Winston, D. J. Articles by Boeckh, M. Related Collections Transplantation Free Research Articles Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study Drew J. Winston1, Jo-Anne H. Young2, Vinod Pullarkat3, Genovefa A. Papanicolaou4, Ravi Vij5, Estil Vance6, George J. Alangaden7, Roy F. Chemaly8, Finn Petersen9, Nelson Chao10, Jared Klein11, Kellie Sprague12, Stephen A. Villano13, and Michael Boeckh14 1 University of California, Los Angeles Medical Center; 2 University of Minnesota Medical Center, Minneapolis; 3 City of Hope National Medical Center, Duarte, CA; 4 Memorial Sloan-Kettering Cancer Center, New York, NY; 5 Washington University School of Medicine, St Louis, MO; 6 Baylor University Medical Center, Dallas, TX; 7 Wayne State University & Karmanos Cancer Center, Detroit, MI; 8 University of Texas M. D. Anderson Cancer Center, Houston; 9 University of Utah and the LDS Hospital, Salt Lake City; 10 Duke University Medical Center, Durham, NC; 11 Loyola University Medical Center, Maywood, IL; 12 Tufts-New England Medical Center, Boston, MA; 13 ViroPharma, Exton, PA; and 14 Fred Hutchinson Cancer Research Center, Seattle, WA The anti-cytomegalovirus (CMV) activity and safety of oral maribavir in CMV-seropositive allogeneic stem-cell transplant recipients were evaluated in a randomized, double-blind, placebo-controlled, dose-ranging study. After engraftment, 111 patients were randomized to receive CMV prophylaxis with maribavir (100 mg twice daily, 400 mg once daily, or 400 mg twice daily) or placebo. Within the first 100 days after transplantation, the incidence of CMV infection based on CMV pp65 antigenemia was lower in each of the respective maribavir groups (15%, P = .046; 19%, P = .116; 15%, P = .053) compared with placebo (39%). Similarly, the incidence of CMV infection based on plasma CMV DNA was lower in each of the respective maribavir groups (7%, P = .001; 11%, P = .007; 19%, P = .038) compared with placebo (46%). Anti-CMV therapy was also used less often in patients receiving each respective dose of maribavir (15%, P = .001; 30%, P = .051; 15%, P = .002) compared with placebo (57%). There were 3 cases of CMV disease in placebo patients but none in the maribavir patients. Adverse events, mostly taste disturbance, nausea, and vomiting, were more frequent with maribavir. Maribavir had no adverse effect on neutrophil or platelet counts. These results show that maribavir can reduce the incidence of CMV infection and, unlike ganciclovir, does not cause myelosuppression. This trial is registered at www.ClinicalTrials.gov as #NCT00223925 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Cytomegalovirus: time for a requiem? Jayesh Mehta Blood 2008 111: 5265-5266. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020